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The recent explosion of scientiﬁc interest in the gut microbiota has dramatically advanced our understanding of the
complex pathophysiological interactions between the gut and multiple organs in health and disease. Emerging
evidence has revealed that the gut microbiota is signiﬁcantly altered in patients with chronic kidney disease (CKD),
along with impaired intestinal barrier function. These alterations allow translocation of various gut-derived products
into the systemic circulation, contributing to the development and progression of CKD and cardiovascular disease
(CVD), partly mediated by chronic inﬂammation. Among potentially toxic gut-derived products identiﬁable in the
systemic circulation, bacterial endotoxin and gut metabolites (e.g., p-cresyl sulfate and trimethylamine-N-oxide) have
been extensively studied for their immunostimulatory and atherogenic properties. Recent studies have also suggested
similar biological properties of bacterial DNA fragments circulating in the blood of patients with CKD, even in the
absence of overt infections. Despite the accumulating evidence of the gut microbiota in CKD and its therapeutic
potential for CVD, the precise mechanisms for multidirectional interactions between the gut, kidney, and heart
remain poorly understood. This review aims to provide recent evidence on the associations between the gut
microbiota, CKD, and CVD, and summarize current understanding of the potential pathophysiological mechanisms
underlying the “gut–kidney–heart” axis in CKD.
Keywords: bacterial DNA, cardiovascular disease, chronic kidney disease, constipation, end-stage renal disease,
microbiome, permeability, uremic toxins
Introduction
Chronic kidney disease (CKD) is a signiﬁcant public health problem worldwide with
increasing prevalence and poor outcomes such as cardiovascular disease (CVD), end-stage
renal disease (ESRD), and mortality, consuming a disproportionate amount of ﬁnancial
resources (16, 49). The increased risk of CVD in patients with CKD is not fully accounted for
and supported by traditional cardiovascular (CV) risk factors, such as dyslipidemia,
hypertension, and diabetes mellitus (111), and low-grade chronic inﬂammation, one of the
so-called non-traditional CV risk factors, has been implicated as a primary shared risk factor
of the excess risk of CVD in this unique population (2, 9, 48). Considerable efforts have been
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established to reduce the inﬂammatory load in patients with CKD primarily by targeting its
known causative factors; however, they have been proven largely unsuccessful (39). Hence,
the substantial disease burden attributable to inﬂammation remains unresolved.
Over the past few decades, the characteristics and functions of gut microbiota have been
extensively studied, and a number of studies have revealed that the alteration of gut
microbiota (i.e., gut dysbiosis) plays a central role in the pathogenesis of many diseases
including CKD and CVD, often referred to as the “gut–kidney” and “gut–heart” axes,
respectively (12, 74). Several factors such as impaired intestinal barrier and gut-derived toxic
products have been suggested to contribute to these relationships partly mediated by systemic
inﬂammation (12), suggesting that the gut is a potential cause of CKD-related complications
and more importantly could serve as a novel therapeutic target for CVD in CKD (73).
However, the precise mechanisms for the possible multidirectional interactions between the
gut, kidney, and heart remain poorly understood.
In this review, we describe recent evidence on the association between the gut
microbiota, CKD, and CVD and summarize current understanding of the potential patho-
physiological mechanisms underlying the “gut–kidney–heart” axis in CKD (Fig. 1).
Composition of the Gut Microbiota
The human gastrointestinal tract harbors a complex community of more than 100 trillion
individual organisms (106). The gut microbiota encodes at least 150-fold more genes than the
human genome, which is also known as the gut microbiome (94). The introduction of high-
throughput microbial DNA sequencing technologies has enabled proﬁling of diverse microbial
Fig. 1. Schematic representation of the gut–kidney–heart axis. TMAO: trimethylamine-N-oxide
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communities in the gut, providing evidence that the overall composition and abundance of the
gut microbiota vary signiﬁcantly among geographically separated human populations, while
dominant members of the gut microbiota are similar across the globe and are independent of
race and gender (53). In general, the gut microbiota in healthy adults is dominated by two
bacterial phyla, Firmicutes and Bacteroidetes, out of over 50 bacterial phyla; and other bacterial
phyla include Actinobacteria, Proteobacteria, Cyanobacteria, and Fusobacteria (17, 93). Given
a constant diet, the composition of the gut microbiota remains stable over time within an
individual (20), which however can be easily altered by changes in diet (14).
Host–Microbiota Interaction in Health and Disease
For millions of years, the gut microbiota has coevolved with the human host and their proper
interactions provide the host with various symbiotic beneﬁts. Under physiological conditions,
the gut microbiota participates in a variety of metabolic activities and has thus been
recognized as a metabolically active endogenous organ in itself (74). These complementary
metabolic activities include synthesis of certain vitamins (30), degradation of undigestible
plant polysaccharides and oxalates (32), and biotransformation of conjugated bile acids (34).
Therefore, changes in the composition and function of the gut microbiota, such as an increase
in Firmicutes to Bacteroidetes ratio, have indeed been associated with numerous disease
states including hypertension (1), heart failure (46), CVD (8), and CKD (65).
Short-chain fatty acids (SCFAs) and host physiology
One of the mechanisms by which the alteration of gut microbiota is linked to these conditions is
through reduced production of SCFAs, such as acetate, propionate, and butyrate. SCFAs are the
products of bacterial fermentation of plant-derived carbohydrates mainly by Bacteroidetes and
Firmicutes (50), and play a vital role in regulating the homeostasis of human body and
progression of diseases (64). Speciﬁcally, SCFAs serve as important energy resources for
colonic epithelial cells (36) and maintain the integrity of the epithelial barrier function by
regulation of tight junction proteins including occluding, claudin-1, and zonula occludens-1
(104). Furthermore, SCFAs can protect the intestinal epithelium via enhancement of the
modulation of host immune responses by two major SCFA signaling mechanisms: inhibition
of histone deacetylases (HDACs) and activation of a certain G protein-coupled receptors
(GPRs) (33, 89, 95). The HDACs are enzymes that prevent DNA transcription and thereby
regulate gene expression. Inhibition of HDACs in colonocytes and mucosal immune cells by
SCFAs could therefore lead to suppression of the nuclear factor-kappa beta (NF-κB) in several
types of cells in the mucosal immune system, thereby inﬂuencing transcription of inﬂammatory-
associated genes, including those that code for proinﬂammatory cytokines [e.g., interleukin-6
(IL-6) and tumor necrosis factor-alpha (TNF-α)] (10, 110). In fact, increased NF-κB activation
was found in colonic biopsies from patients with Crohn’s disease, which was inhibited by
applying butyrate to the specimen, accompanied by a reduction in the release of several
proinﬂammatory cytokines (27, 77). Meanwhile, the GPRs, particularly GPR43, GPR41, and
GPR109A, have been identiﬁed as colonic receptors for SCFAs and play a major role in the
regulation of inﬂammatory processes partly through suppressing the expression of NF-κB and
promoting the differentiation of colonic regulatory T cells (79, 92). Of interest, recent studies
have shown that SCFAs inﬂuence blood pressure regulation partly through GPR41, which is
also expressed in the endothelium and is shown to mediate a hypotensive response (60, 68). This
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is also supported by the ﬁnding that the GPR41 gene-deleted mice developed isolated systolic
hypertension with increased vascular ﬁbrosis, increased pulse wave velocity, and cardiac
hypertrophy compared with wild-type littermates (60).
Taken together, SCFAs serve as key regulators for modulation of gut integrity, energy
homeostasis, immune function, and blood pressure response. Therefore, a state of reduced
abundance of SCFA-producing taxa in the gut could in turn negatively affect various
disease conditions, such as inﬂammatory bowel disease, colorectal cancer, hypertension,
and CVD (5, 21).
The Gut Microbiota in CKD
Emerging evidence has revealed that, compared with healthy individuals, patients with CKD
show a signiﬁcant alteration of the gut microbiota, with increased numbers of speciﬁc
microbial taxa of both aerobic and anaerobic bacteria (78). In a study comparing the
composition of the gut microbiota between CKD and control rats, a signiﬁcant difference
was found in the abundance of 175 bacterial operational taxonomic units (OTUs), which are
microbial genomic sequences clustered by sequence similarity, with notable decreases in
certain families of the Bacteroidetes and Firmicutes phyla, especially Lactobacillaceae and
Prevotellaceae families, in the CKD rats (99). The study also revealed a signiﬁcant difference
in the abundance of 190 bacterial OTUs between patients with ESRD and healthy individuals
(99). Other studies have shown that the number of Enterobacteriaceae (especially Enter-
obacter, Klebsiella, and Escherichia), Enterococci, and Clostridium perfringens was signiﬁ-
cantly higher in the stool of patients with ESRD than healthy controls (29, 103).
One of the contributing factors to the gut dysbiosis in CKD may be the uremic milieu.
Bacterial urease in the gut, for example, hydrolyzes urea and produces large quantities of
ammonia and ammonium hydroxide, which increase luminal pH and result in the alteration
of gut microbial compositions (98, 108). Other factors potentially contributing to the
altered gut microbiota in CKD include restricted intake of dietary ﬁber (35), medication
use (e.g., antibiotics, phosphate binders, and iron) (42, 47, 96), slow intestinal transit time
(109), and metabolic acidosis (24). It may be important to note that most of these factors have
also been suggested as causative factors for the intestinal barrier dysfunction, which has
recently been increasingly recognized in patients with CKD (3, 55, 91).
Intestinal Barrier Dysfunction in CKD
Intestinal barrier dysfunction and bacterial translocation have been well described in certain
diseases, such as inﬂammatory bowel disease (52), portal hypertension (51), and heart
failure (101). Emerging evidence has revealed that the intestinal epithelial barrier is altered
both structurally and functionally in patients with CKD, resulting in increased gut perme-
ability (55). Several factors have been suggested to account for the gut barrier dysfunction in
CKD, including gut dysbiosis (41, 87), slow intestinal transit time (109), low dietary ﬁber
intake (44), metabolic acidosis (41), gut ischemia and edema (87), iron therapy (102), and
frequent use of antibiotics (15). Urease enzyme produced by certain microbiota families, such
as Enterobacteriaceae, for example, hydrolyzes urea in the gut, leading to the formation of
ammonium hydroxide. The high amount of ammonium hydroxide could then induce
disruption of the intestinal epithelial tight junctions, characterized by the depletion of
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occludin, claudin-1, and zona occludens proteins (99). Recent evidence has also revealed that
dysfunction of tight junction proteins results in reduced expression of nuclear factor erythroid
2-related factor 2 (NRF2), a regulator of antioxidant defense genes, thus elevating levels of
oxidative stress in the uremic milieu (45). The resultant increase in gut permeability, in turn,
allows translocation of gut-derived toxins, bacterial fragments, and intact bacteria through the
bowel wall into the systemic circulation, which has been considered as a key contributor to
the activation of host inﬂammatory responses, potentially leading to excess morbidity and
mortality in CKD (100).
Gut-Derived Products and CVD in CKD
Among possible gut-derived products identiﬁable in the systemic circulation, bacterial
endotoxin [i.e., lipopolysaccharide (LPS)], and gut metabolites [e.g., p-cresyl sulfate and
trimethylamine-N-oxide (TMAO)] have been extensively studied for their immunostimula-
tory and atherogenic properties (19, 90, 107). Recently, using the technique of bacterial DNA
ampliﬁcation, similar biological properties have also been recognized for circulating bacterial
DNA fragments among patients with CKD, even in the absence of overt infections (87).
Bacterial endotoxin and CVD in CKD
Bacterial endotoxin, a LPS constituent of the external cell wall of most Gram-negative
bacteria, is continuously produced in the gut and translocated into the systemic circulation
across the intestinal barrier (54, 63). Patients with CKD are characteristically exposed to
signiﬁcant endotoxemia due to altered gut permeability and/or endotoxin contamination of
dialysis water (23, 72). A previous study showed that the levels of circulating endotoxin
increased with advancing CKD stages, with the highest levels observed in patients receiving
dialysis (54). In addition, accumulating evidence has revealed the strong association between
endotoxemia and systemic inﬂammation, which has been implicated in the development and
progression of atherosclerosis and subsequent CVD in CKD (22). Toll-like receptor 4
(TLR4), which is expressed on various tissues including cells of the innate immune system,
smooth muscle, and endothelial cells and binds to circulating endotoxin, plays a central role
in the inﬂammatory process (63). Endotoxin-mediated signaling through TLR4 stimulates
IL-1 receptor-associated kinase via mutant myeloid differentiation primary response 88 and
myeloid differentiation protein 2, and the subsequent recruitment of TNF receptor-associated
factor 6 leads to the activation of the NF-κB and the release of various proinﬂammatory
cytokines (59, 88). These inﬂammatory responses result in endothelial cell injury, transfor-
mation of macrophages to foam cells, and procoagulant activity, and could consequently
contribute to the development and progression of atherosclerosis (11).
Microbiota metabolites and CVD in CKD
p-Cresyl sulfate and indoxyl sulfate. Protein fermentation by certain gut bacteria results in the
generation of various metabolites, some of which exert toxic effects and thus are called uremic
toxins (25). p-Cresyl sulfate and indoxyl sulfate are the two major gut-derived uremic toxins
(31). p-Cresyl sulfate, a 188-Da protein-bound solute, originates from sulfation of the
intestinally generated p-cresol, which is a colonic fermentation product of the amino acid
tyrosine and phenylalanine (13). Intestinal bacteria also have tryptophanase that converts
tryptophan to indole, which is subsequently absorbed and metabolized by the liver to indoxyl
sulfate (13). Both p-cresyl sulfate and indoxyl sulfate are normally secreted by the proximal
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tubular cells of the kidneys. However, as kidney function declines, these two uremic toxins
accumulate progressively and exert deleterious effects on various tissues and organs, such as
renal tubular cell damage, endothelial dysfunction, leukocyte activation, coagulation distur-
bances, insulin resistance, and cardiac ﬁbrosis and hypertrophy (69, 97). p-Cresyl sulfate, for
example, increases expression of DNA methyltransferases 1, 3a, and 3b isoforms that suppress
Klotho gene expression in the renal tubular cells and also induces epithelial-to-mesenchymal
transition-like changes through activation of the renal renin angiotensin aldosterone system/
transforming growth factor-beta pathway, contributing to kidney injury and ﬁbrosis (84, 85). In
addition, it induces nicotinamide adenine dinucleotide phosphate oxidase activity and reactive
oxygen species production in cardiomyocytes, enhancing cardiac apoptosis and resulting in
diastolic dysfunction (28). In line with these experimental observations, several clinical studies
have shown that elevated levels of p-cresyl sulfate and indoxyl sulfate are associated with
higher risk of CKD progression, CVD, and mortality (4, 56).
Trimethylamine-N-oxide. TMAO is a circulating organic compound derived from the
metabolism of dietary L-carnitine and choline by intestinal bacteria, which was recently
found to directly promote atherosclerosis in rodents (38, 105). Although the precise
mechanisms whereby TMAO induces atherosclerosis remain elusive, the prevailing
hypothesis is that TMAO causes alteration of cholesterol and sterol metabolism and promotes
pro-atherogenic foam cell formation in the arterial wall by increasing the expression of
scavenger receptors on macrophages or by restricting reverse cholesterol transport out of
these cells (38, 105). Recent clinical studies have demonstrated that elevated levels of TMAO
are independently associated with future CV events in non-CKD and non-dialysis-dependent
CKD populations (80). Although this association has not yet been well conﬁrmed in the
ESRD population receiving hemodialysis (81), most current evidence supports the mecha-
nistic link between TMAO and CV outcomes.
Bacterial DNA fragments and CVD in CKD
Due to its highly conserved sequence of 16S ribosomal RNA gene in the genome, circulating
bacterial DNA fragment is the most easily and consistently detectable component that could
also be easily discerned from human DNA (87). In recent years, increasing attention has been
paid to circulating bacterial DNA fragments for their immunostimulatory properties and
novel pathogenic potential for CVD in patients with CKD, particularly among those with
ESRD receiving dialysis (87). Bacterial DNA contains unmethylated cytosine–guanine
dinucleotide, with two purine 5′ and two pyrimidine 3′ (CpG) terminations. These are
structures required to interact with TLR9 (bacterial DNA receptor), which triggers a cell
signaling pathway including activation of the mitogen-activated protein kinases and the
NF-κB (43). In polymorphonuclear neutrophils, bacterial DNA exerts profound effects on
neutrophil functions by promoting neutrophil trafﬁcking, inducing chemokine expression,
regulating expression of adhesion molecules, enhancing phagocyte activity, and rescuing
neutrophils from constitutive apoptosis (18). It also promotes the survival of mononuclear
cells and induces IL-6 from those cells (62, 75). The inﬂammatory responses induced by
bacterial DNA fragments have also been involved in endothelial injury through induction of
endothelial cell apoptosis in hemodialysis patients (57). Furthermore, an experimental study
has suggested a direct effect of circulating bacterial DNA fragments on the CV system via
suppression of cardiac myocyte contraction (66). In fact, some observational studies have
demonstrated signiﬁcant associations of circulating bacterial DNA level with serum
C-reactive protein and IL-6 levels and subsequent risk of CV events in patients with
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ESRD (86). Of note, the association with CV events was found to be less substantial for
plasma endotoxin (vs. bacterial DNA) levels, suggesting that, compared to plasma endotoxin,
which is a cell wall component of only Gram-negative bacteria, circulating bDNA fragments
that derive from both Gram-positive and -negative bacteria could play a more predominant
role in the development of CVD (87).
Gut Microbiota-Targeted Interventions for CVD in CKD
Improved understanding of the pathological roles of gut dysbiosis has triggered interest in the
development of various therapeutic interventions, which aimed at reestablishing symbiotic
status of the gut microbiota or reducing absorption of gut-derived metabolites (73). These
include dietary modiﬁcations (37) and the administration of probiotics (i.e., live micro-
organisms) (61), prebiotics (i.e., non-digestible food ingredients) (40), synbiotics (i.e., both
probiotics and prebiotics) (26), oral adsorbents (e.g., AST-120) (76), and genetically
engineered bacteria (71). Importantly, however, all of these previous studies have examined
the therapeutic effect on surrogate measures; hence, it remains unclear whether these
interventions actually reduce CV risk in patients with CKD.
As another gut microbiota targeted intervention for CVD in CKD, laxatives may be a
potentially novel treatment option. In patients with CKD, the prevalence of constipation has
been reported to be higher than in the general population (7). Since gastrointestinal motility
and gut microbiota are closely interrelated and exert reciprocal effects on each other (70),
constipation, one of the clinical forms of gut dysbiosis (67), is recently considered to be
involved in the pathogenesis of atherosclerosis partly through chronic inﬂammation
induced by bacterial endotoxins (6) and/or gut-derived metabolites (90), potentially
contributing to adverse clinical outcomes (82, 83). In addition, a recent study demonstrated
that lubiprostone, a chloride channel activator used for constipation treatment, ameliorated
the CKD progression and the accumulation of uremic toxins by improving the altered gut
microbiota in CKD mice (58). Given the high prevalence of constipation, the substantial
alterations of gut microbiota in CKD and the increasing roles of the gut in the disposal of
uremic toxins with declining kidney function, the administration of laxatives might be a
potentially attractive gut microbiota-targeted therapeutic intervention for CVD in patients
with CKD.
Conclusions
While the relationship between gut health and human disease processes has long been
recognized, with the earliest evidence dating back to more than 2,000 years ago when
Hippocrates famously stated that “All disease begins in the gut,” the recent explosion of
scientiﬁc interest in the gut microbiota has dramatically advanced our understanding of the
complex pathophysiological interactions between the gut and multiple organs. Emerging
evidence on the association between gut microbiota, CKD, and CVD has provided novel
mechanistic insight into the “gut–kidney–heart” axis, emphasizing the importance of the gut
as a potential cause of CKD-related complications. Furthermore, these ﬁndings have opened
new avenues for the development of personalized, gut microbiota-targeted therapeutic
strategies for CVD in CKD, which if proved to be effective, will have a substantial impact
on the CKD management. More in-depth basic and clinical research is needed to further
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understand the pathophysiological mechanisms underlying the “gut–kidney–heart” axis to
ultimately improve the outcomes of patients with CKD.
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